Last €8.68 EUR
Change Today +0.12 / 1.40%
Volume 32.8K
TNG On Other Exchanges
EN Paris
As of 11:35 AM 09/23/14 All times are local (Market data is delayed by at least 15 minutes).

transgene sa (TNG) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/19/14 - €13.71
52 Week Low
08/8/14 - €7.09
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for TRANSGENE SA (TNG)

Related News

No related news articles were found.

transgene sa (TNG) Related Businessweek News

No Related Businessweek News Found

transgene sa (TNG) Details

Transgene S.A., a biopharmaceutical company, engages in the research, design, development, and manufacture of therapeutic vaccines and immunotherapeutic products to treat cancers and chronic infectious diseases. Its principal products under Phase II clinical trials include TG4010 for the treatment of metastatic non-small cell lung cancer in combination with chemotherapy; Pexa-Vec primarily for the treatment for liver cancer; TG4001, a therapeutic vaccine for oropharyngeal cancer caused by an infection by the human papilloma virus (HPV); and TG4040 for the treatment of chronic hepatitis C. The company has agreements with Novartis for the development of TG4010 to treat various cancers; Jennerex Biotherapeutics, Inc. for the development and marketing of Pexa-Vec, an oncolytic product; and European Organization for Research and Treatment of Cancer for the development of TG4001 to treat HPV induced head and neck cancers. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene S.A. is a subsidiary of TSGH SAS.

262 Employees
Last Reported Date: 04/17/14
Founded in 1979

transgene sa (TNG) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: €72.2K
Compensation as of Fiscal Year 2013.

transgene sa (TNG) Key Developments

Transgene Announces Unaudited Consolidated Earnings Results for the Six Month Period Ended June 30, 2014; Provides Guidance for the Full Year of 2014

Transgene announced unaudited consolidated earnings results for the six month period ended June 30, 2014. For the period, according to IFRS, the company reported revenue of EUR 6,279,000 against EUR 6,714,000 a year ago. Operating loss was EUR 23,792,000 against EUR 22,235,000 a year ago. Loss before tax was EUR 24,358,000 against EUR 23,040,000 a year ago. Net loss was EUR 25,113,000 against EUR 23,166,000 a year ago. Diluted loss per share was EUR 0.65 against EUR 0.73 a year ago. Net cash used in operating activities was EUR 23,821,000 against EUR 23,607,000 a year ago. Acquisition of property, plant and equipment was EUR 831,000 against EUR 1,122,000 a year ago. Acquisition of intangible assets was EUR 97,000 against EUR 126,000 a year ago. The company expects to spend EUR 50 million EUR 55 million to fund its operations for the full year of 2014.

Transgene SA Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 01:40 PM

Transgene SA Presents at Rodman & Renshaw 16th Annual Global Investment Conference, Sep-10-2014 01:40 PM. Venue: New York Palace Hotel – 455 Madison Avenue, New York, NY 10022, United States.

Transgene Announces Results in an Update from the Phase 2b Part of TIME Trial with TG4010 in Advanced Non-Small Cell Lung Cancer

Transgene SA announced promising results in an update incorporating more mature data from the Phase 2b part of the Phase 2b/3 TIME trial with TG4010 MUC-1 targeted immunotherapy in patients with advanced non-small cell lung cancer (NSCLC). Following an analysis conducted with a more mature dataset, the primary endpoint of progression-free survival (PFS) to validate the TrPAL predictive biomarker was met in the normal TrPAL group. The high TrPAL group had not yet met the required number of events to conduct the primary analysis. Importantly, in the subgroup of patients of non-squamous histology (191 out of 217 patients), the vast majority of patients in the trial, the difference in PFS was statistically significant and clinically meaningful with a p value of 0.02 and a stratified log rank hazard ratio (HR) of 0.71 [0.51; 0.98] (intent-to-treat analysis). As expected, in this non-squamous population, the PFS HR observed was even more notable in the normal TrPAL subgroup of patients. TG4010 was well tolerated, and the nature and incidence of adverse events in the TG4010 arm were consistent with previous Phase 2 clinical trials. To date, over 350 patients have been treated with TG4010. Data for overall survival, a secondary endpoint in the TIME trial, although not yet mature, are suggesting a clinically meaningful improvement in line with the one observed with the PFS data. Detailed results from the TIME trial, including overall survival, are expected to be presented at a major medical meeting later this year. The Company will be interacting with regulatory authorities to discuss the data from the TIME trial in preparation of the phase 3 part of the trial.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TNG:FP €8.68 EUR +0.12

TNG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for TNG.
View Industry Companies

Industry Analysis


Industry Average

Valuation TNG Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TRANSGENE SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at